No price history available for this symbol yet.
Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
Sector
Drug Manufacturers - Specialty & Generic
Neuland Laboratories Limited functions as a global developer and provider of active pharmaceutical ingredients (APIs), with a significant market presence in India, Europe, the United States, and other international territories. These vital compounds are employed across a diverse range of medical conditions, addressing areas such as respiratory ailments, cardiovascular health, fungal infections, convulsive disorders, central nervous system conditions, bacterial infections (including fluoroquinolone-based treatments), psychotic disorders, and Parkinson's disease. In addition to API production, the firm also delivers tailored custom manufacturing solutions and specialized peptide synthesis services. Founded in 1984, Neuland Laboratories Limited is headquartered in Hyderabad, India.
www.neulandlabs.comNo one on the platform currently holds NEULANDLAB.BO.
No tracked institution reports a position in NEULANDLAB.BO as of their last filing.
No one on the platform has traded NEULANDLAB.BO yet.
Consensus-seeded revenue, margins, and exit multiples. This is a scenario tool, not investment advice.
Consensus does not cover every selected forecast year. Later assumptions are extrapolated from available analyst estimates.
| Metric | Historical average | My assumptions | ||||
|---|---|---|---|---|---|---|
| 1 year | 5 years | 10 years | Low | Mid | High | |
| ROIC % | 17.1% | 15.4% | 10.3% | — | — | — |
| Rev. Growth % | 41.0% | 17.1% | ||||
| Profit Margin % | 18.0% | 15.4% | 10.1% | |||
| Free Cash Flow Margin % | -2.9% | 4.7% | 1.0% | |||
| Exit P/E | — | — | — | |||
| Exit P/FCF | — | — | — | |||
| Desired Annual Return % | — | — | — | |||
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
At today's price, your expected annual return is — on the P/E track.
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
| Year | Est. revenue | Growth | Est. EPS | EPS range | Fwd P/E | # Analysts |
|---|---|---|---|---|---|---|
| 2027 | $24.3B | +37.9% | $368.61 | $355.59–$381.39 | — | 5 |
| 2028 | $29.2B | +20.0% | $491.79 | $464.40–$514.90 | — | 5 |
| 2029 | $34.6B | +18.7% | $624.50 | $612.34–$640.08 | — | 1 |
Forward consensus · growth is YoY vs the prior fiscal-year estimate · Fwd P/E at the current price · source: Financial Modeling Prep
Beat consensus in 3 of the last 8 reported quarters
| Reported | Est. EPS | Actual | Surprise |
|---|---|---|---|
| 2026-08-05 | $60.01 | $115.00 | +91.6% |
| 2026-05-12 | $78.16 | $165.76 | +112.1% |
| 2026-02-09 | $56.52 | $37.00 | -34.5% |
| 2025-11-07 | $54.92 | $75.50 | +37.5% |
| 2025-07-31 | $51.53 | $10.80 | -79.0% |
| 2025-05-15 | $44.26 | $21.64 | -51.1% |
| 2025-02-10 | $48.15 | $47.91 | -0.5% |
| 2024-11-06 | $50.15 | $25.60 | -49.0% |
| Symbol | Price | Today | Mkt cap | P/E |
|---|---|---|---|---|
| NEULANDLAB.BONeuland Laboratories Limited | $22522.85 | -3.87% | $289.5B | — |
| APLLTD.NSAlembic Pharmaceuticals Limited | $824.75 | +1.70% | $162.1B | — |
| ASTRAZEN.BOAstraZeneca Pharma India Limited | $6693.35 | -1.23% | $167.4B | — |
| ASTRAZEN.NSAstraZeneca Pharma India Limited | $6695.50 | -1.02% | $167.4B | — |
| ERIS.BOEris Lifesciences Limited |
| $1311.00 |
| -3.25% |
| $181.7B |
| — |
| ERIS.NSEris Lifesciences Limited | $1310.10 | -3.35% | $181.6B | — |
| JUBLPHARMA.BOJubilant Pharmova Limited | $1009.60 | -1.51% | $160.1B | — |
Source: Financial Modeling Prep · peers by sector/industry